Hodgkin Lymphoma News and Research

RSS
Cancer Australia releases new data on childhood cancer stage at diagnosis

Cancer Australia releases new data on childhood cancer stage at diagnosis

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Verastem doses first patient in Phase I/II clinical trial of duvelisib in combination with venetoclax

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Phase 2 clinical study reports best outcomes to date for older Hodgkin lymphoma patients

Study reveals how socioeconomic status affects racial, ethnic disparities in childhood cancer survival

Study reveals how socioeconomic status affects racial, ethnic disparities in childhood cancer survival

Hospitals battle for control over fast-growing heart-valve procedure

Hospitals battle for control over fast-growing heart-valve procedure

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

FDA approves drug for rare, hard-to-treat types of non-Hodgkin lymphoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments

Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

Drug used in stem cell therapy may protect against smoke-induced lung injury

Drug used in stem cell therapy may protect against smoke-induced lung injury

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Clinical trial targets metastatic colorectal cancer with new combination therapy

Clinical trial targets metastatic colorectal cancer with new combination therapy

Some tumors use two levels of protection against immune system, shows study

Some tumors use two levels of protection against immune system, shows study

Study finds increase in lifestyle-related cancers over the past decade

Study finds increase in lifestyle-related cancers over the past decade

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

New 'lymphoma micro-reactor' device targets chemo-resistant tumors

New 'lymphoma micro-reactor' device targets chemo-resistant tumors

New insights into breast implant-associated anaplastic large-cell lymphoma

New insights into breast implant-associated anaplastic large-cell lymphoma